Search clinical trials for: Ciprofloxacin DPI (BAYQ3939)

Total 1600 results

Bayer
Novartis

Completed

Summative Usability Study of Ciprofloxacin Dry Powder for Inhalation Using Placebo

Bronchiectasis | Pulmonary Disease, Chronic Obstructive

United States
Bayer
Novartis

Completed

Ciprofloxacin Dry Powder for Inhalation in Non-cystic Fibrosis Bronchiectasis (Non-CF BE) (RESPIRE 1)

Bronchiectasis

Spain, United States, New Zealand, Japan, France, Australia, Germany, Denmark, Israel, United Kingdom, Latvia, Italy, Slovakia, Argentina
Bayer

Completed

Efficacy and Safety of CIPRO XR Versus CIPRO IR in Patients With Complicated Urinary Tract Infections (EMERON)

Urinary Tract Infection

Italy
Bayer

Completed

Ciprofloxacin Special Drug Use Investigation - To Investigate the Safety and Efficacy in Patients With Ciprofloxacin iv Administration Without Dilution

Infection

Japan
Bayer
Novartis

Completed

Study to Evaluate the Safety and Efficacy of Ciprofloxacin (Inhaled) in Patients With Cystic Fibrosis

Cystic Fibrosis

United States, Israel, Germany, Canada, Australia, Sweden, Denmark, Norway, United Kingdom
Bayer

Completed

Study in COPD (Chronic Obstructive Pulmonary Disease) Subjects to Investigate Safety, Tolerability, and Pharmacokinetics of Ciprofloxacin After Single Dose Inhalations of 50 mg and 75 mg Ciprofloxacin Inhalation Powder

Pulmonary Disease, Chronic Obstructive | Infection

Germany
Bayer

Completed

To Evaluate the Safety, Tolerability, Pulmonary Deposition, Pharmacokinetics and Pharmacodynamics of Ciprofloxacin Inhale in Japanese Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD, GOLD II-III)

Pulmonary Disease, Chronic Obstructive

Japan
Bayer

Completed

Study To Evaluate The Efficacy And Safety Of Ciprofloxacin Extended-Release (Cipro® XR) 1000 mg Tablets Given Once Daily For 7 To 14 Days In The Treatment Of Patients 18 Years Or Older With Complicated Urinary Tract Infections Caused By Pseudomonas Aeruginosa And Other Common Uropathogens

Urinary Tract Infections

United States
Bayer
Novartis

Completed

Evaluation of Cipro Inhale in Patients With Non-cystic Fibrosis Bronchiectasis

Bronchiectasis

Spain, Germany, Australia, United States, United Kingdom, Sweden
Bayer

Completed

Assessment of the Safety and Efficacy of Ciproxan-I.V. in Daily Clinical Practice - Analysis Results From a Post-marketing Surveillance

Infection

Japan
Bayer

Completed

Special Drug Use Investigation of Ciproxan Injection in Pediatrics

Cystitis / Pyelonephritis / Cystic Fibrosis / Anthrax

Japan
Bayer

Completed

Cipro Inhaler for Cystic Fibrosis Children Ages 6-12

Pseudomonas Infection

United States
Memorial Sloan Kettering Cancer Center
Weill Medical College of Cornell University

Completed

MRI and Diffusion Imaging of Eloquent Brain Areas to Optimize Brain Tumor Resection Planning

Brain Cancer

United States
Bayer

Completed

A Phase III Study to Evaluate the Safety, Efficacy and Pharmacokinetics/Pharmacodynamics of BAYQ3939 in Patients With Bacterial Pneumonia

Pneumonia

Japan
Bayer

Completed

A Phase IV Study of Cipro XR in Uncomplicated UTI (EXPRESS)

Urinary Tract Infections
Bayer

Completed

Study to Characterize Lung Deposition, Pharmacokinetics, Safety and Tolerability of Single Inhalations of Radiolabeled Ciprofloxacin Dry Powder in Healthy Subjects and Patients With Chronic Lung Diseases

Respiratory System

Germany
Bayer

Completed

Cipro® XR in Therapeutic Response and Activity (eXtRa) - Assessing Symptom Relief in Urinary Tract Infections

Urinary Tract Infection

United States
Bayer
Novartis

Completed

Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE) (RESPIRE 2)

Bronchiectasis

China, Hong Kong, Germany, Philippines, Russian Federation, United States, Australia, Austria, Czechia, Taiwan, Brazil, Korea, Republic of, Netherlands, Thailand, Latvia, Romania, Turkey, Serbia, Portugal, Bulgaria, Slovakia, Poland, Argenti... and more
Bayer
Novartis Pharmaceuticals

Completed

Study to Evaluate the Safety and Pharmacokinetics of Inhaled Ciprofloxacin in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Germany
Umeå University
County Council of Norrbotten, Sweden

Completed

Lifestyle Intervention in Primary Health Care - the Björknäs Study

Hypertension | Obesity | Type 2 Diabetes | Dyslipidemia

Sweden
GlaxoSmithKline

Completed

Comparative Study of ELLIPTA Dry Powder Inhaler (DPI) Versus DISKUS DPI Used With HandiHaler DPI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States
Bayer
Novartis

Completed

Study to Evaluate the Safety and Pharmacokinetics of Inhaled Ciprofloxacin in Patients With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)

Disease, Pulmonary

Germany
Debiopharm International SA

Recruiting

A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors

Pancreatic Ductal Adenocarcinoma (PDAC) | Colorectal Cancer (CRC) | Clear Cell Renal Cell Cancer (ccRCC)

France, Australia
GlaxoSmithKline

Completed

An Open-label Study to Evaluate Correct Use and Ease of Use of the ELLIPTA DPI in Pediatric Subjects With Asthma

Asthma

Canada, United States
Sanofi

Completed

A PK Comparability Study of Two Different Amlitelimab Drug Products in Healthy Participants

Healthy Volunteers

United States
Celon Pharma SA
National Center for Research and Development, Poland

Completed

Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Depression

Major Depressive Disorder

Poland
AlgiPharma AS
AlgiPharma Australia Pty. Ltd.

Unknown

A Phase 2b Randomised, Placebo Controlled Study of OligoG in Patients With Cystic Fibrosis

Cystic Fibrosis

Australia
Celon Pharma SA
National Center for Research and Development, Poland

Completed

Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Bipolar Depression

Bipolar Depression

Poland
Nocion Therapeutics

Completed

Placebo-controlled, Single and Multiple Dose Study in Healthy Volunteers and Refractory Chronic Cough Patients to Assess the Safety, Tolerability, and Pharmacokinetics of Two Formulations of NTX-1175

Refractory Chronic Cough

United States
Chiesi Farmaceutici S.p.A.

Completed

Safety, Tolerability and Efficacy of 28-day Inhaled CHF 6001 DPI in COPD Patients

COPD

United Kingdom, Ireland
Celon Pharma SA
National Center for Research and Development, Poland

Completed

Safety and Pharmacokinetic Study of Inhaled Esketamine in Healthy Volunteers

Healthy Volunteers

Poland
University of North Carolina, Chapel Hill
University of Texas at Austin

Completed

Evaluation of a Dry Powder Aerosol Dispersion Mechanism by Radiolabeling Techniques (DPI)

Adult Healthy Volunteers

United States
Chiesi Farmaceutici S.p.A.

Completed

An Open Label Placebo Study to Assess the Inhalation Profile in Asthmatic Patients Using the Nexthaler® Dry Powder Inhaler (DPI) Device (NEXThalerPIF)

Asthma

Italy
Forest Laboratories
PPD

Terminated

Study of the Safety and Efficacy of Apadenoson for Detection of Myocardial Perfusion Defects Using SPECT MPI (ASPECT)

Coronary Artery Disease

United States, Brazil
Forest Laboratories
PPD

Terminated

Study of the Safety and Efficacy of Apadenoson for Detection of Myocardial Perfusion Defects Using SPECT MPI (ASPECT2)

Coronary Artery Disease

United States, Argentina, Belgium, Brazil, Netherlands
Chiesi Farmaceutici S.p.A.

Completed

An Open Label Placebo Study To Assess The Inhalation Profile Obtained By Acoustic Monitoring In COPD Patients Using The NEXThaler DPI (PIF3)

COPD

Italy
Medical College of Wisconsin
University of Wisconsin, Milwaukee; Children's Hospital and Health System Foundation... and other collaborators

Completed

Evaluating a New Way to Prepare Parents of Hospitalized Children for Discharge and Management of Child at Home

Patient Discharge

United States
AstraZeneca
Parexel

Terminated

Evaluation of AZD8154 Concentrations in Blood

Asthma

Germany
GlaxoSmithKline

Completed

A Study to Investigate the Efficacy, Safety, and Tolerability of Repeat Doses of Inhaled GSK2269557 in Adults With Persistent, Uncontrolled Asthma

Pulmonary Disease, Chronic Obstructive

Germany
AstraZeneca
Parexel

Completed

A Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD7594 Administered Once Daily by Inhalation in Asthmatic Subjects

Asthma

United States, Germany, South Africa, Ukraine, Japan, Hungary, Poland, Bulgaria
Poitiers University Hospital

Terminated

Short or Long Schemes of Antibiotic Prophylaxis for Prostate Biopsy

Men Who Must Undergo a Prostate Biopsy Related to Prostate Cancer Suspicion.

France
Sanofi
Regeneron Pharmaceuticals

Completed

Comparison of the Pharmacokinetics and Safety of Two SAR231893 (REGN668) Drug Products in Healthy Subjects

Healthy

United States
GlaxoSmithKline

Completed

Pharmacokinetic Profile of Four Formulations of Fluticasone Furoate (FF) Using Unit Dose Dry Powder Inhaler (UD-DPI) Compared With FF ELLIPTA® Presentation

Asthma

Australia
Chiesi Farmaceutici S.p.A.

Completed

Efficacy of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) (CHF 5993)Administered Via Dry Powder Inhaler (DPI) in Chronic Obstructive Pulmonary Disease (COPD) (TRI-D)

Chronic Obstructive Pulmonary Disease

Bulgaria
GlaxoSmithKline

Completed

Study to Evaluate Safety, Tolerability and Pharmacokinetics of GSK2269557 to Japanese Healthy Subjects

Pulmonary Disease, Chronic Obstructive

Japan
BeyondSpring Pharmaceuticals Inc.
Covance; ICON plc

Completed

Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 3 (Protective-1)

Chemotherapy-induced Neutropenia

China, Russian Federation, United States, Ukraine
University of California, Davis

Completed

Casinomacropeptide and Satiety (CMP2)

Appetite Disorders | Lack of Satiety | Excess Intake of Macronutrients

United States
GlaxoSmithKline

Completed

Safety and Efficacy Study of Fluticasone Furoate/Vilanterol (FF/VI) Fixed Dose Combination (FDC) Compared to FF Alone in Subjects With Asthma

Asthma

United States, Argentina, Japan, Poland, Canada, Russian Federation, Spain, Germany, Hungary, South Africa, Italy, Mexico, Romania, Bulgaria, China, Lithuania
Swiss Paraplegic Research, Nottwil

Completed

Exploring Functional Paralysis With Advanced Magnetic Resonance Modalities

Paralysis | Functional Neurological Symptom Disorder | Conversion Disorder With Weakness/Paralysis

Switzerland
AstraZeneca

Completed

A Clinical Trial in Healthy Volunteers and Patients With Mild Asthma to Investigate a New Medicine (AZD4604) for the Treatment of Asthma

Asthma

United Kingdom

3

Subscribe